NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, Forecast & News

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.07 by $1.77. The biopharmaceutical company had revenue of $59.49 million for the quarter, compared to the consensus estimate of $58.33 million. Vanda Pharmaceuticals had a net margin of 55.49% and a return on equity of 38.90%. The business's revenue for the quarter was up 21.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.13 earnings per share. View Vanda Pharmaceuticals' Earnings History.

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Vanda Pharmaceuticals.

4 brokerages have issued twelve-month target prices for Vanda Pharmaceuticals' stock. Their forecasts range from $17.00 to $26.00. On average, they anticipate Vanda Pharmaceuticals' share price to reach $20.00 in the next year. This suggests a possible upside of 41.7% from the stock's current price. View Analyst Price Targets for Vanda Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 sell rating and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vanda Pharmaceuticals.

News coverage about VNDA stock has been trending somewhat negative on Monday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vanda Pharmaceuticals earned a news impact score of -1.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Vanda Pharmaceuticals.

Vanda Pharmaceuticals saw a drop in short interest in January. As of January 15th, there was short interest totalling 4,010,000 shares, a drop of 10.3% from the December 31st total of 4,470,000 shares. Based on an average daily volume of 556,300 shares, the days-to-cover ratio is presently 7.2 days. Approximately 7.8% of the company's stock are short sold. View Vanda Pharmaceuticals' Current Options Chain.

Some companies that are related to Vanda Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Array Biopharma (ARRY), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH), Nektar Therapeutics (NKTR) and Inovio Pharmaceuticals (INO).

Vanda Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Strs Ohio (0.09%), New York State Teachers Retirement System (0.07%), Arizona State Retirement System (0.07%), Louisiana State Employees Retirement System (0.03%) and Campbell & CO Investment Adviser LLC (0.03%). Company insiders that own Vanda Pharmaceuticals stock include Gian Piero Reverberi, Gunther Birznieks, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View Institutional Ownership Trends for Vanda Pharmaceuticals.

VNDA stock was sold by a variety of institutional investors in the last quarter, including Arizona State Retirement System, Strs Ohio and Louisiana State Employees Retirement System. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gian Piero Reverberi, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View Insider Buying and Selling for Vanda Pharmaceuticals.

VNDA stock was purchased by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC and New York State Teachers Retirement System. View Insider Buying and Selling for Vanda Pharmaceuticals.

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VNDA stock can currently be purchased for approximately $14.11.

Vanda Pharmaceuticals has a market capitalization of $752.63 million and generates $193.12 million in revenue each year. The biopharmaceutical company earns $25.20 million in net income (profit) each year or $0.48 on an earnings per share basis. Vanda Pharmaceuticals employs 270 workers across the globe.View Additional Information About Vanda Pharmaceuticals.

The official website for Vanda Pharmaceuticals is http://www.vandapharma.com/.

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]